CFTR调节器度对囊性纤维化患者临床反应的影响
Ashritha R Chalamalla1, Elizabeth Baker2, Kevin J Ryan2
1Arkansas Children's Research Institute.
The European respiratory journal
|February 19, 2026
概括
治疗elexacaftor/tezacaftor/ivacaftor (ETI) 的较低药物度与囊性纤维化 (CF) 患者的汗水化物水平较差相关. 这凸显了个性化剂量的必要性,因为CYP3A5基因型没有影响药物水平.
科学领域:
- 药物基因组学 药物基因组学
- 囊性纤维化治疗药物治疗方法
- 离子通道生理学 离子通道生理学
背景情况:
- 囊性纤维化 (CF) 由CF跨膜导电性调节器 (CFTR) 变体引起,导致化物运输受损和多器官问题.
- CFTR调节器可以改善治疗,但患者的反应有所不同,可能是由于药物度的不同.
研究的目的:
- 在CF患者中评估elexacaftor/tezacaftor/ivacaftor (ETI) 度.
- 研究CYP3A5基因型对ETI度和汗液化物水平的影响.
主要方法:
- 97名参与者接受ETI治疗的多中心研究.
- 量化ETI药物度和确定CYP3A5基因型.
- 相关性和回归分析将药物水平,基因型和汗液化物反应联系起来.
主要成果:
- 观察到高可变性血水平的elexacaftor,tezacaftor,和 ivacaftor. 这两种药物都具有很高的可变性.
- CYP3A5基因型没有显著影响ETI药物度.
- 较低的ETI度与较高的汗液化物水平有关,即使对共变量进行调整后,也表明结果更差.
结论:
- 较低的ETI药物度与CF患者的汗水化物水平较差相关.
- 药物度的变化表明需要个性化剂量策略来改善CF治疗.
- 标准的CYP3A5基因型确定不太可能指导ETI剂量决定.
相关概念视频
01:23Cystic Fibrosis: Pathogenesis
1.1K
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.1K
01:24Cystic Fibrosis: Management
658
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
658
01:15Pharmacodynamic Models: Linear Concentration–Effect Model
91
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing...
91
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97